Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
CPhI North AmericaCPhI North America
Not Confirmed
Not Confirmed
02-04 June, 2026
Not Confirmed
Not Confirmed
03-05 June, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
CPhI North AmericaCPhI North America
Industry Trade Show
Not Confirmed
02-04 June, 2026
Industry Trade Show
Not Confirmed
03-05 June, 2026
Digital content
NEWS #PharmaBuzz
07 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/luye-pharma-announces-us-launch-of-erzofri-paliperidone-palmitate-extended-release-injectable-suspension-for-the-treatment-of-schizophrenia-and-schizoaffective-disorder-302421464.html
28 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/luye-pharma-announces-us-fda-approval-of-erzofri-paliperidone-palmitate-extended-release-injectable-suspension-for-treating-schizophrenia-and-schizoaffective-disorder-302208155.html
06 Jun 2024
// PRESS RELEASE
07 Feb 2024
// BIOSPECTRUM ASIA
https://www.biospectrumasia.com/news/25/23688/chinas-luye-pharma-partners-with-korea-based-myung-in-pharm-to-improve-alzheimers-related-dementia-treatment.html
05 Apr 2023
// BIOSPECTRUM ASIA
https://www.biospectrumasia.com/news/25/22232/luye-pharma-duopharma-to-expand-accessibility-of-cholesterol-management-products-in-malaysia.html
16 Jan 2023
// PHARMACEUTICAL TECHNOLOGY
https://www.pharmaceutical-technology.com/news/fda-schizophrenia-treatment-rykindo/
Drugs in Development
Details:
14-C LPM3770164 is a radiolabeled compound drug, which is currently being evaluated in Phase I clinical studies for the treatment of huntington disease.
Lead Product(s): 14-C LPM3770164
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Radiolabeled Compound
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2026
Lead Product(s) : 14-C LPM3770164
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mass Balance Study of [14C] LPM3770164 in Healthy Participants
Details : 14-C LPM3770164 is a radiolabeled compound drug, which is currently being evaluated in Phase I clinical studies for the treatment of huntington disease.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
April 08, 2026
Details:
LY03020 is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of schizophrenia.
Lead Product(s): LY03020
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 09, 2026
Lead Product(s) : LY03020
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LY03020 is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 09, 2026
Details:
LPM6690176 is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of colorectal neoplasms.
Lead Product(s): LPM6690176,Bevacizumab,Fluorouracil,Calcium Folinate,Irinotecan Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2026
Lead Product(s) : LPM6690176,Bevacizumab,Fluorouracil,Calcium Folinate,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LPM6690176 is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of colorectal neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2026
Details:
LY03021 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of depressive disorder, major.
Lead Product(s): LY03021
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 27, 2026
Lead Product(s) : LY03021
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LY03021 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of depressive disorder, major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2026
Details:
LYB004 is a vaccine drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Herpes Zoster.
Lead Product(s): LYB004
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 30, 2025
Lead Product(s) : LYB004
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adul...
Details : LYB004 is a vaccine drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Herpes Zoster.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 30, 2025
Details:
LY03020 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Schizophrenia.
Lead Product(s): LY03020
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 18, 2025
Lead Product(s) : LY03020
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Food Effect Study of LY03020 in Healthy Subjects
Details : LY03020 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 18, 2025
Details:
(LY01021) is currently being evaluated in Phase II clinical studies for the treatment of Ovarian Hyperstimulation Syndrome.
Lead Product(s): LY01021
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 19, 2025
Lead Product(s) : LY01021
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : (LY01021) is currently being evaluated in Phase II clinical studies for the treatment of Ovarian Hyperstimulation Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 19, 2025
Details:
LY03020 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Schizophrenia.
Lead Product(s): LY03020
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2025
Lead Product(s) : LY03020
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
Details : LY03020 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 17, 2025
Details:
LY03017 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Alzheimer Disease.
Lead Product(s): LY03017
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 20, 2025
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
Details : LY03017 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 20, 2025
Details:
BA1301 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): BA1301
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2025
Details : BA1301 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 15, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : RX
Registration Country : USA
Dosage Form : SUSPENSION, EXTENDED REL...
Brand Name : ERZOFRI
Dosage Strength : 39MG/0.25ML (39MG/0.25...
Packaging :
Approval Date : 2024-07-26
Application Number : 216352
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : SUSPENSION, EXTENDED REL...
Brand Name : ERZOFRI
Dosage Strength : 78MG/0.5ML (78MG/0.5ML...
Packaging :
Approval Date : 2024-07-26
Application Number : 216352
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : SUSPENSION, EXTENDED REL...
Brand Name : ERZOFRI
Dosage Strength : 117MG/0.75ML (117MG/0....
Packaging :
Approval Date : 2024-07-26
Application Number : 216352
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : SUSPENSION, EXTENDED REL...
Brand Name : ERZOFRI
Dosage Strength : 156MG/ML (156MG/ML)
Packaging :
Approval Date : 2024-07-26
Application Number : 216352
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : SUSPENSION, EXTENDED REL...
Brand Name : ERZOFRI
Dosage Strength : 234MG/1.5ML (156MG/ML)
Packaging :
Approval Date : 2024-07-26
Application Number : 216352
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : SUSPENSION, EXTENDED REL...
Brand Name : ERZOFRI
Dosage Strength : 351MG/2.25ML (156MG/ML...
Packaging :
Approval Date : 2024-07-26
Application Number : 216352
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Transdermal Patch
Brand Name : Rivasur twice weekly hour...
Dosage Strength : 4.6mg/24hours
Packaging :
Approval Date : 13/02/2024
Application Number : 68897
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Transdermal Patch
Brand Name : Rivasur twice weekly hour...
Dosage Strength : 9.5mg/24hours
Packaging :
Approval Date : 13/02/2024
Application Number : 68897
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Authorized
Registration Country : Spain
Dosage Form : Transdermal Patch
Brand Name : Rotigotina Luye
Dosage Strength : 4MG
Packaging :
Approval Date : 08-03-2024
Application Number : 89421
Regulatory Info : Authorized
Registration Country : Spain
Regulatory Info : Authorized
Registration Country : Spain
Dosage Form : Transdermal Patch
Brand Name : Rotigotina Luye
Dosage Strength : 2MG
Packaging :
Approval Date : 08-03-2024
Application Number : 89419
Regulatory Info : Authorized
Registration Country : Spain
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Inspections and registrations
ABOUT THIS PAGE
Share 
